Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Multi‐Gene Pharmacogenetics and Blood Pressure Control in Patients with Hypertension
Johnson, Micah William, Sprissler, Ryan , Olson, Thomas P. , Beenken, Greg William, Snyder, Eric M.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.942.1 Get It

Introduction Several common and functional genes are known to contribute to renal, blood vessel, and cardiac functional characteristics associated with sodium (Na + ) handling, vascular reactivity, and cardiac output, respectively. Many of these same genes are suggested to contribute to differential responsiveness to blood pressure (BP) therapy. Few studies have explored the simultaneous phenotypic consequence of multiple genes critical for BP control. Despite a significant impulse of the medical community towards personalized medicine, BP therapy is typically guided by algorithms that do not include a patient's genetic information. Purpose The purpose of this study was to determine the impact of 14 genes on time to BP control in response to common BP therapy, with a specific focus on genes associated with drug metabolism and protein function in the kidney, the blood vessels, and the heart. Methods Eighty‐six patients completed one study visit consisting of a buccal swab for DNA extraction and genotyping, measurement of ambulatory BP, and a medical chart review for objective BP history. Genes in the analysis included those that encode for one drug metabolizing enzyme (CYP2D6), renal Na + handling (SCNN1A, WNK1, SLC12A3, and Alpha Adducin), vascular function (angiotensin, ACE, angiotensin‐II receptor type‐I, and renin), and cardiac function (the β 1 and β 2 adrenergic receptors ADRB1 and ADRB2, respectively). Results Genetic variation of WNK1 (rs1159744) demonstrated differential responses to diuretic therapy (determined as those with blood pressure under 140/90 vs. those above 140/90 according to genotype)(WNK1=GG>CG/CC, P<0.05). Genes that encode ADRB1 (rs1801252), ADRB2 (rs1042713), and CYP2D6 (rs3892097) demonstrated differential response to β‐blocker therapy (ADRB1=Ser/Ser>SerThr/ThrThr, ADRB2=GG>AG/AA, CYP2D6=CC>CT/TT, P<0.05). Genes that encode angiotensin (rs699), ACE (rs1799752), and renin (rs12750834) demonstrated differential response to ACE‐inhibition and angiotensin receptor blockade (angiotensin=CT/TT>CC, ACE=Ins/Ins>InsDel/DelDel, renin=AG/AA>GG, p<0.05). Conclusion These results demonstrate that genetic variants encoding proteins involved in renal Na + handling, vascular function, and cardiac output influence response to BP therapy for their respective drug classes. Support or Funding Information Funded by Geneticure
Time to Blood Pressure Control According to Drug Class in Patients with Hypertension
Johnson, Micah William, Sprissler, Ryan , Olson, Thomas P. , Beenken, Greg William, Snyder, Eric M.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.941.12 Get It

Introduction Hypertension is one of the most important preventable contributors to disease and death worldwide and represents the most common condition seen in the primary care setting. Approximately one in three adults living in the US has hypertension. Despite the prevalence and impact of hypertension, little data exists on the average time to blood pressure (BP) control in US patients and time to control according to common BP medication classes. Purpose Therefore, the purpose of this study was to assess the average time to BP control in adults with controlled hypertension, according to drug class. Methods For this study we assessed how long (in months) and how many clinic visits were needed in order to control BP according to common medication classes in patients with existing hypertension. The study was performed at two clinical sites where patients came in for one visit for an in‐clinic assessment of BP and for completion of a patient survey regarding their history of BP. The primary care physician performed a chart review for a detailed objective BP history. Results Ninety‐nine patients completed all aspects of the study (age=58±0.8yrs., %female=46, height=169±1.0cm, weight=86±1.4kg, BMI=29.9±0.4m/kg 2 ). The average initial BP was 151±2mmHg systolic (SBP), 91±1mmHg diastolic, and 111±1mmHg mean arterial (MAP). Patients demonstrated a significant drop in BP with therapy (SBP=16mmHg, DBP=10mmHg, MAP=12mmHg). Patients were prescribed an average of 1.8 BP medications (62% on ACE‐inhibitor, 42% on diuretic, 33% on β‐blocker, 27% on angiotensin receptor blocker, and 16% on Ca + channel blocker). The average time to BP control was 14.9 months or 3.6 clinic visits. Patients on a diuretic had the longest time to BP control, while patients on a Ca + channel blocker had the shortest time to control (diuretic=19.5±10.4, angiotensin receptor blocker=22.8±13.1, ACE‐inhibitor=22.2±11.4, β‐blocker=24.5±16.9, Ca + channel blocker=9.9±4.5 months, pANOVA<0.05). In contrast, patients on a Ca + channel blocker had significantly more clinic visits to attain BP control (diuretic=4.5±0.6, ACE‐inhibitor=3.1±0.4, angiotensin receptor blocker=3.9±0.6, β‐blocker=4.9±0.7, Ca + channel blocker=5.1±0.7 visits). Conclusion These results suggest important differences in the time to BP control, and the number of office visits necessary for BP control according to common classes of hypertension therapies. Funding was provided by Geneticure, LLC Support or Funding Information Funded by Geneticure
Hybrid Oncocytic Tumors (HOTs) in Birt-Hogg-Dubé Syndrome Patients—A Tale of Two Cities
Mannan, Rahul , Zhang, Yuping , Chinnaiyan, Anya, Rangaswamy, Roshni, Chugh, Seema , Cao, Xuhong , Hafez, Khaled S., Vaishampayan, Ulka N. , McKenney, Jesse K. , Gupta, Sounak , Tretiakova, Maria , Argani, Pedram , Mehra, Rohit , Vaishampayan, Ulka , Tretiakova, Maria S , Wang, Xiaoming , Su, Fengyun , Wang, Rui , Skala, Stephanie L. , Picken, Maria M. , Alaghehbandan, Reza , Chinnaiyan, Arul , Dhanasekaran, Saravana Mohan

Mayo Clinic

American Journal of Surgical Pathology | November 23, 2023 | Volume: 48 | Issue: 2 | Pages: 163-173

10.1097/pas.0000000000002152 | PMID 37994665 Get It

Birt-Hogg-Dubé (BHD) syndrome is associated with an increased risk of multifocal renal tumors, including hybrid oncocytic tumor (HOT) and chromophobe renal cell carcinoma (chRCC). HOT exhibits heterogenous histologic features overlapping with chRCC and benign renal oncocytoma, posing challenges in diagnosis of HOT and renal tumor entities resembling HOT. In this study, we performed integrative analysis of bulk and single-cell RNA sequencing data from renal tumors and normal kidney tissues, and nominated candidate biomarkers of HOT, L1CAM, and LINC01187, which are also lineage-specific markers labeling the principal cell and intercalated cell lineages of the distal nephron, respectively. Our findings indicate the principal cell lineage marker L1CAM and intercalated cell lineage marker LINC01187 to be expressed mutually exclusively in a unique checkered pattern in BHD-associated HOTs, and these 2 lineage markers collectively capture the 2 distinct tumor epithelial populations seen to co-exist morphologically in HOTs. We further confirmed that the unique checkered expression pattern of L1CAM and LINC01187 distinguished HOT from chRCC, renal oncocytoma, and other major and rare renal cell carcinoma subtypes. We also characterized the histopathologic features and immunophenotypic features of oncocytosis in the background kidney of patients with BHD, as well as the intertumor and intratumor heterogeneity seen within HOT. We suggest that L1CAM and LINC01187 can serve as stand-alone diagnostic markers or as a panel for the diagnosis of HOT. These lineage markers will inform future studies on the evolution and interaction between the 2 transcriptionally distinct tumor epithelial populations in such tumors.
Cardiovascular and metabolic effects of MANP. a novel GC-A activator, in human hypertension with metabolic syndrome
Bailey, Kent R. , Johnson, Bradley K. , Benike, Sherry L., Cabassi, Aderville , Burnett, John C. , Cannone, Valentina , Ma, Xiao , McKie, Paul M. , Iyer, Seethalakshmi , Scott, Christopher G. , Chen, H, Miller, Wayne L.

Mayo Clinic

European Heart Journal | November 22, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.2365 Get It

Abstract Background/Introduction Hypertension (HTN) and metabolic syndrome (MetS) are both leading risk factors for major cardiovascular diseases, which frequently coexist as a complicated cardiometabolic disorder. The cardiac hormone atrial natriuretic peptide (ANP) plays a key role in both blood pressure and metabolic regulation through activation of the guanylyl cyclase-A receptor (GC-A) and the second messenger 3’,5’ cyclic guanosine monophosphate (cGMP). Indeed, ANP decreases blood pressure, induces lipolysis by increasing plasma levels of non-esterified fatty acids (NEFA) and improves insulin-sensitivity. MANP is a new Mayo Clinic designed natriuretic peptide consisting of the native ANP with a 12-amino-acid C-terminus extension and its biological actions are mediated by the GC-A/cGMP pathway. MANP is less susceptible to neprilysin degradation and exert more sustained cGMP dependent biological actions than ANP. Purpose In a proof-of-principle human study, for the first time we aimed to determine the cardiovascular and metabolic properties of MANP, a novel ANP analog, in the clinical setting of HTN with MetS. Methods We conducted a double-blind, placebo-controlled trial in 22 patients (17 receiving MANP) with HTN and MetS involving single subcutaneous injection of MANP (2.5 µg/kg) or placebo (NCT03781739). Blood pressure (BP) and circulating cGMP were monitored for 24 hours post treatment. Circulating metabolic parameters including insulin, glucose, non-esterified fatty acids (NEFA) and insulin resistance (HOMA-IR) and insulin sensitivity (HOMA-IS) indexes were assessed for the first 4 hours post treatment. Results Compared to baseline, MANP increased plasma cGMP at 30 minutes (delta: 4.8 ± 2.0 pmol/mL, P = 0.02) and 1 hour (delta: 2.9 ± 1.3 pmol/mL, P = 0.03) post injection. At 6 hours, systolic BP decreased by 5.7 ± 2.9 mmHg (P = 0.06) in the MANP group, whereas no reduction in BP was observed in placebo group. Among the 17 subjects receiving MANP, lower baseline cGMP levels were associated with greater mean reductions in systolic BP (ρ = 0.66, P = 0.005). After MANP injection, glucose levels decreased at 2 (delta: -4.7 ± 2.1 mg/mL, P = 0.04) and 4 hours (delta: -13.1 ± 3.9 mg/mL, P = 0.003) compared to baseline while insulin levels remained stable. During the first 4 hours post injection, we also observed a trend of increase in insulin sensitivity index (HOMA2-IS) and decrease in insulin resistance index (HOMA2-IR) with MANP, both were opposite to the trends in placebo. At 1 hour post MANP administration, NEFA increased by 108.2 ± 37.4 µM compared to baseline (P = 0.01). Conclusion(s) Our findings support the favorable cardiovascular and metabolic actions of MANP as a potential therapeutic strategy for HTN with MetS.
Standardizing nomenclature in regional anesthesia: an ASRA-ESRA Delphi consensus study of upper and lower limb nerve blocks
El‐Boghdadly, Kariem , Albrecht, Éric , Wolmarans, Morné , Mariano, Edward R. , Kopp, Sandra L. , Perlas, Anahi , Thottungal, Athmaja , Tulgar, Serkan , Adhikary, Sanjib Das , Barrington, Michael J. , Blanco, Rafael, Boretsky, Karen , Breebaart, Margaretha , Laurent, David Burckett-St , Carvalho, Brendan , Chin, Ki Jinn , Coppens, Steve , Costache, I. , Dam, Mette , Desmet, Matthias , Egeler, C., Elsharkawy, Hesham , Bendtsen, Thomas Fichtner , Fox, Ben, Franco, Carlo D. , Gautier, Philippe , Grant, Stuart A. , Grape, Sina , Guheen, Carrie R., Hebbard, Peter , Hernandez, Nadia , Hogg, Rosemary , Holtz, Margaret, Ihnatsenka, Barys , Ilfeld, Brian M. , Kalagara, Hari , Kessler, Paul, Kwofie, Kwesi , Le-Wendling, Linda , Lirk, Philipp , Ludwin, Danielle, Macfarlane, Alan , Μakris, Alexandros , McCartney, Colin J. L. , McDonnell, John G., McLeod, Graeme , Memtsoudis, Stavros G. , Merjavy, Peter , Moran, EML , Nader, Antoun , Neal, Joseph M. , Niazi, Ahtsham U. , Njathi-Ori, Catherine , OʼDonnell, Brian D. , Oldman, Matt, Orebaugh, Steven L. , Parras, Teresa, Pawa, Amit , Peng, Philip , Pulos, Bridget P. , Saporito, Andrea , Sauter, Axel R. , Sebastian, Maria Paz , Sinha, Sanjay K. , Stimpson, James, Tang, Raymond , Tsui, Ban C. H. , Turbitt, Lloyd , Uppal, Vishal , Geffen, Geert J. van, Vermeylen, Kris , Vlassakov, Kamen, Volk, Thomas , Xu, Jeff L. , Elkassabany, Nabil , Kopp, Sandra , Tulgar, Serkan , Adhikary, Sanjib , Altıparmak, Başak , Bloc, Sébastien , Boretsky, Karen , Bowness, James , Carvalho, Brendan , Chin, Ki Jinn , Chuan, Alwin , Costache, Ioana , Dam, Mette , Dhir, Shalini , Elsharkawy, Hesham , Bendtsen, Thomas Fichtner , Franco, Carlo D , Grape, Sina , Harbell, Monica W , Hebbard, Peter , Ilfeld, Brian M , Ip, Vivian H Y , Johnson, Rebecca L , Kwofie, M Kwesi , Le-Wendling, Linda , Lobo, Clara , Macfarlane, Alan James Robert , Makris, Alexandros , McLeod, Graeme , Memtsoudis, Stavros G , Moran, E M Louise , Nader, Antoun , Neal, Joseph M , Niazi, Ahtsham U , Orebaugh, Steven L , Pawa, Amit , Peng, Philip , Porter, Steven B , Sala-Blanch, Xavier , Sauter, Axel R , Schwenk, Eric S , Sebastian, Maria Paz , Soffin, Ellen M , Tsui, Ban C H , Turbitt, Lloyd , Uppal, Vishal , van Geffen, Geert J , Vermeylen, Kris , Vlassakov, Kamen , Xu, Jeff L , Elkassabany, Nabil M , Mariano, Edward R , El-Boghdadly, K , Volk, Thomas , Kalagara, Hari , Albrecht, Eric , Coppens, Steve , Wolmarans, Morné , Gadsden, Jeff , Aguirre, José Alejandro , Agur, Anne Maria Reet , Bedforth, Nigel M. , Blanco, Rafael, Chelly, Jacques E. , Chuan, Alwin , Harbell, Monica W. , Ip, Vivian , Johnson, Rebecca L. , Kessler, Paul, Lobo, Clara , Porter, Steven B. , Sala‐Blanch, Xavier , Schwenk, Eric S. , Sidhu, Navdeep S. , Soffin, Ellen M.

Mayo Clinic

Regional Anesthesia & Pain Medicine | November 22, 2023 | Volume: 49 | Issue: 11 | Pages: 782-792

10.1136/rapm-2023-104884 | PMID 38050174 Get It

Background Inconsistent nomenclature and anatomical descriptions of regional anesthetic techniques hinder scientific communication and engender confusion; this in turn has implications for research, education and clinical implementation of regional anesthesia. Having produced standardized nomenclature for abdominal wall, paraspinal and chest wall regional anesthetic techniques, we aimed to similarly do so for upper and lower limb peripheral nerve blocks. Methods We performed a three-round Delphi international consensus study to generate standardized names and anatomical descriptions of upper and lower limb regional anesthetic techniques. A long list of names and anatomical description of blocks of upper and lower extremities was produced by the members of the steering committee. Subsequently, two rounds of anonymized voting and commenting were followed by a third virtual round table to secure consensus for items that remained outstanding after the first and second rounds. As with previous methodology, strong consensus was defined as ≥75% agreement and weak consensus as 50%–74% agreement. Results A total of 94, 91 and 65 collaborators participated in the first, second and third rounds, respectively. We achieved strong consensus for 38 names and 33 anatomical descriptions, and weak consensus for five anatomical descriptions. We agreed on a template for naming peripheral nerve blocks based on the name of the nerve and the anatomical location of the blockade and identified several areas for future research. Conclusions We achieved consensus on nomenclature and anatomical descriptions of regional anesthetic techniques for upper and lower limb nerve blocks, and recommend using this framework in clinical and academic practice. This should improve research, teaching and learning of regional anesthesia to eventually improve patient care.
Durable responses at 24 months with high-frequency spinal cord stimulation for nonsurgical refractory back pain
Johnson, Curtis A. , Kloster, Daniel, Calodney, Aaron , Kosek, Peter, Pilitsis, Julie G. , Bendel, Markus A. , Wu, Chengyuan, Cherry, Taissa, Lad, Shivanand P. , Goree, Johnathan , Lyons, Mark , Sack, Andrew , Bruce, Diana, Bharara, Manish , Province‐Azalde, Rose , Caraway, David , Bendel, Markus, Patel, Naresh P. , Jameson, Jessica, Johnson, Curtis, Petersen, Erika , Yu, Cong , Sayed, Dawood , Kapural, Leonardo

Mayo Clinic

Journal of Neurosurgery: Spine | November 18, 2023 | Volume: 40 | Issue: 2 | Pages: 229-239

10.3171/2023.9.spine23504 | PMID 37976509 Get It

OBJECTIVE The objective of this study was to evaluate the 24-month durability of pain relief, function, quality of life, and safety outcomes for patients with nonsurgical refractory back pain (NSRBP) treated with high-frequency spinal cord stimulation (SCS) within a large, national, multicenter randomized controlled trial (RCT). METHODS Following the completion of an RCT comparing high-frequency SCS plus CMM with CMM alone for the treatment of NSRBP, patients gave additional consent for a follow-up extension to 24 months. Presented is the cohort analysis of all patients treated with high-frequency SCS following the optional crossover at 6 months. The outcomes assessed to 24 months included responder rate of ≥ 50% pain relief measured according to the visual analog scale [VAS]), disability (Oswestry Disability Index [ODI]), quality of life (EQ-5D 5-level [EQ-5D-5L]), opioid reduction. RESULTS Of the 125 patients who received a permanent implant, 121 completed the 12-month follow-up, 101 gave additional consent for extended follow-up, and 98 completed the 24-month follow-up. At 24 months after implantation, the mean back pain VAS score was reduced by 73% and the responder rate was 82%. ODI and EQ-5D-5L both improved by at least double the minimal clinically important difference for each measure. No unexpected adverse events were observed, and the rates of serious adverse events (3.4%) and device explantations (4.8%) were low. CONCLUSIONS The addition of high-frequency SCS to CMM in patients with NSRBP offers profound improvements at 24 months in pain, function, quality of life, and reduced opioid use. This study provides much-needed evidence to inform current clinical practice for managing patients with NSRBP.
Continuing Education: Improving Athletic Trainers’ Knowledge of Musculoskeletal Diagnostic Ultrasound Through a Physician-Led Longitudinal Ultrasound Course
Johnson, Wade O. , Jelsing, Elena J., Williams, Amanda , Pinkney, Joshua J., Asplund, Chad A., Schroeder, Allison N. , Kruse, Ryan C.

Mayo Clinic

Athletic Training Education Journal | November 17, 2023 | Volume: 18 | Issue: 4 | Pages: 234-242

10.4085/1062-6050-037.22 Get It

Context Musculoskeletal (MSK) diagnostic ultrasound (US) is increasingly being utilized by physicians to evaluate athletes in outpatient clinics, on the sidelines, and in athletic training facilities. Having a thorough understanding of MSK US will help athletic trainers (ATs) better assist physicians who perform MSK US. Objective To determine if a longitudinal 6-month MSK anatomy and US course would increase ATs’ ability to acquire, label, and optimize US images of normal structures and improve their overall confidence in assisting with performing US and to determine if demographic factors, work-related factors, or higher self-reported confidence was associated with better performance. Design Prospective cohort study. Setting Academic institution. Other Participants Seventeen ATs working with sports medicine physicians at 3 institutions. Interventions Longitudinal 6-month MSK anatomy and US course. Main Outcome Measures Ultrasound image scores (normal structures scored on a 5-point scale) were assessed precourse, during the course, and postcourse. Scores were compared across time points for the assessed body regions (knee, ankle/foot, shoulder, elbow/wrist/hand, and hip). Associations with demographic factors, US experience, and AT self-reported confidence were explored. Results Seventeen ATs completed the course. There was a significant difference among the average overall precourse (average: 1.34/5, range: 0/5 to 4.23/5), during-course (average = 3.53/5; range, 2.6/5 to 4.37/5), and postcourse (average = 3.83/5; range, 2.33/5 to 4.67/5) image scores [χ2(2) = 24.47, P &lt; .001]. There was a significant positive correlation between the numbers of days (rs[17] = 0.62, P = .01) and hours (rs[17] = 0.55, P = .02) per week that the AT spent observing or performing US scanning and the postcourse overall image scores. The ATs’ confidence in identifying structures when they scan and postcourse overall image scores were marginally correlated but not significant (rs[17] = 0.47, P = .06). Conclusions A comprehensive longitudinal MSK diagnostic US course may have resulted in significant improvements in an AT’s ability to acquire, label, and optimize US images of normal MSK structures that are commonly injured by active persons.
P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL
Plesner, Torben , Kumar, Shaji , Hulin, Cyrille , Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand , Pei, Huiling , Kaila, S., Matt, K., Gries, Katharine S. , Carson, Robin, Borgsten, F., Facon, Thierry T.F. , Usmani, Saad Z. , Bahlis, Nizar Jacques , Orlowski, Robert Z. , Nahi, Hareth , Mollee, Peter , Ramasamy, Karthik , Roussel, Murielle , Jaccard, Arnaud , Karlin, Lionel , Chari, Ajai , Gupta, Neeraj , Matt, K., Weisel, Katja C , Perrot, Aurore

Mayo Clinic

HemaSphere | November 16, 2023 | Volume: 7 | Issue: S2 | Pages: 18-19

10.1097/01.hs9.0000936192.21618.f2 Get It

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
Kumar, Shaji , Facon, T., Plesner, Torben , Hulin, Cyrille , Goldschmidt, Hartmut , Venner, Christopher P. , Tiab, Mourad, Macro, Margaret , Leleu, Xavier , Pei, Huiling , Krevvata, Maria, Carson, Robin, Borgsten, F., Weisel, Katja C , Moreau, Philippe , Bahlis, Nizar Jacques , Orlowski, Robert Z. , Basu, Supratik , Nahi, Hareth , Quach, Hang , O’Dwyer, Michael , Perrot, Aurore , Raje, Noopur , Frenzel, Laurent , Usmani, Saad Z.

Mayo Clinic

HemaSphere | November 16, 2023 | Volume: 7 | Issue: S2 | Pages: 14-15

10.1097/01.hs9.0000936164.84357.ed Get It

Percutaneous Transseptal Extracorporeal Membrane Oxygenation to Rescue a Failing Right Ventricle in an Animal Model
Castillo‐Larios, Rocio , Pollak, Peter , Chaudhary, Sanjay , Case, J. Brad , Alomari, Mohammad , Song, ZuoRui, Johnson, James L., Narula, Tathagat , Makey, Ian A. , Pollak, Peter M, Alomari, Mohammad , Pham, Si M. , Makey, Ian , Chaudhary, Sanjay , Guru, Pramod

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | November 16, 2023 | Volume: 18 | Issue: 6 | Pages: 583-588

10.1177/15569845231208187 | PMID 37968876 Get It

Objective: We tested the feasibility and effectiveness of a percutaneous atrial transseptal extracorporeal membrane oxygenation (ECMO) cannulation strategy in a right ventricular failure (RVF) model. Methods: We performed 4 nonsurvival porcine experiments. Percutaneous transseptal access was achieved using a steerable introducer. For guidance, we used fluoroscopy, transesophageal echocardiogram (TEE), and intracardiac echocardiography (ICE). A ProtekDuo rapid deployment cannula (LivaNova, London, UK) was advanced across the septum into the left atrium by 2 to 3 cm. Pulmonary hypertension (PH) was induced by partially clamping the pulmonary artery. ECMO flow was cycled from high (2 to 3 L/min) to low (0.2 to 0.3 L/min) over 2 to 3 hours. Results: Transseptal access using TEE and fluoroscopy was successful in 1 animal and unsuccessful in 1 animal. ICE provided optimal visualization for the remaining 2 animals. Mean arterial pressure (MAP) was associated immediately and consistently with high versus low ECMO flow rate (mean difference: 29 ± 3.1 mm Hg, P = 0.004) but was not restored to baseline values. RV pressure values were dynamic. Given time to equilibrate, mean RV pressure was restored to a baseline level. Conclusions: Percutaneous right atrium to left atrium transseptal cannulation relieved PH-RVF. MAP was restored to a viable level, and mean RV pressure was restored to a baseline level. Transseptal ECMO shows promise as a cannulation strategy to bridge patients with PH-RVF to lung transplant.